PBLA Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Panbela Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.25 |
| 52 Week High | US$0.48 |
| 52 Week Low | US$0.23 |
| Beta | 1.27 |
| 1 Month Change | -11.87% |
| 3 Month Change | -22.81% |
| 1 Year Change | -38.32% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Panbela Therapeutics dips 24% on pricing $6M public offering
Sep 30Panbela Therapeutics GAAP EPS of -$1.51
Aug 15Companies Like Panbela Therapeutics (NASDAQ:PBLA) Are In A Position To Invest In Growth
Feb 18
Panbela: Biotech With Updated Patent Protection And Unmet Market Target Indication
Jan 06Will Panbela Therapeutics (NASDAQ:PBLA) Spend Its Cash Wisely?
Nov 02Companies Like Panbela Therapeutics (NASDAQ:PBLA) Are In A Position To Invest In Growth
Jul 15We Think Panbela Therapeutics (NASDAQ:PBLA) Can Afford To Drive Business Growth
Mar 29Shareholder Returns
| PBLA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -16.3% | 0.8% | 1.6% |
| 1Y | -38.3% | -13.8% | 11.7% |
Return vs Industry: PBLA underperformed the US Biotechs industry which returned -14.7% over the past year.
Return vs Market: PBLA underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| PBLA volatility | |
|---|---|
| PBLA Average Weekly Movement | 23.0% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: PBLA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PBLA's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 8 | Jennifer Simpson | www.panbela.com |
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin.
Panbela Therapeutics, Inc. Fundamentals Summary
| PBLA fundamental statistics | |
|---|---|
| Market cap | US$1.21m |
| Earnings (TTM) | -US$37.05m |
| Revenue (TTM) | n/a |
Is PBLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBLA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$37.05m |
| Earnings | -US$37.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -35.2% |
How did PBLA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 09:27 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Panbela Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Joseph Pantginis | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |